Precision Oncology Trends
The latest news on precision oncology research trends.
The assay provides comprehensive genomic information to oncologists from a blood draw, using targeted next-generation sequencing of circulating cell-free DNA.
Two studies, one positive and one negative, give proponents and skeptics more data to parse in debating whether genomically guided treatment has broad value in lung cancer.
One project aims to collect patients' genomic and molecular information in a database, and another aims to tailor treatments based on patients' molecular profiles.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.
The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers.
The promising response rates seen in the SUMMIT trial may provide further reason to broadly test all advanced cervical cancer patients for precision medicine biomarkers.
Results from the Phase II INSPIRE study showed that change in ctDNA from baseline, as gauged by customized assays, predicted response to pembrolizumab.
NRG1 gene fusions, found most commonly in lung and pancreatic cancer, are generating interest among drugmakers as a new precision medicine indication.
The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.